Acute Coronary Syndrome (ACS)
A Clinical Outcomes Study of Darapladib versus Placebo in Persons Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Reduce the incidence of major cardiovascular events in high risk patients following ACS.
Key Inclusion Criteria
- Hospitalized for ACS (unstable angina, non-ST segment elevation myocardial infarction (MI) or ST segment elevation MI)
- Ability to randomize the subject within 30 days after the qualifying ACS event.
- At least 1 additional predictors of cardiovascular risk
Key Exclusion Criteria
No major coronary artery with a blockage of more than 50%